益气化瘀解毒法对慢性萎缩性胃炎伴异型增生大鼠EGFR/MAPK信号通路的影响

目的观察益气化瘀解毒法对慢性萎缩性胃炎(CAG)伴异型增生(Dys)模型大鼠EGFR/MAPK信号通路的影响。方法 60只SPF级健康雄性Wistar大鼠随机分为空白组10只,造模组50只。空白组给予SPF级动物标准饮食喂养,持续至实验结束。造模组采用以120 mg/L的N-甲基-N'-硝基-N-亚硝基胍(MNNG)溶液灌胃,每只5 m L/kg,1次/d为主,配合自由饮用0.1%氨水溶液及进食含0.03%雷尼替丁的颗粒状饲料,3种因素联合建立CAG伴Dys大鼠模型。28周末造模成功后将造模组剩余的30只大鼠随机分为模型组、维酶素组、益气化瘀解毒法组(中药组),每组各10只,均给予SPF级动物标准饮食喂养,并且每天灌胃1次,维酶素组予维酶素悬浊液2 m L/kg(即维酶素0.3 g/kg),中药组予益气化瘀解毒中药3 m L/kg(含生药9 g/kg),模型组予生理盐水3m L/kg。12周后即实验第40周末处死全部大鼠。选用Western blot法对各组大鼠胃窦部黏膜组织中EGFR、ERK1/2、p-ERK1/2蛋白表达进行检测。结果模型组EGFR蛋白表达最高,其次是维酶素组、中药组、空白组;其中,模型组与空白组和中药组比较均有显著性差异(均P0.01),中药组与维酶素组比较有显著性差异(P0.05)、与空白组比较无显著性差异(P0.05)。模型组ERK1/2蛋白表达最高,其次是维酶素组、中药组、空白组;其中,模型组、维酶素组与空白组和中药组比较均有显著性差异(均P0.01),中药组与空白组比较也有显著性差异(P0.01)。模型组p-ERK1/2蛋白表达最高,其次是维酶素组、中药组、空白组;其中,模型组与空白组和中药组比较均有显著性差异(均P0.01),中药组与维酶素组有显著性差异(P0.01)、与空白组比较无显著性差异。结论益气化瘀解毒法可显著抑制EGFR的高表达及EGFR/MAPK细胞信号转导通路的异常激活,这可能是其治疗CAG伴Dys、逆转胃癌前病变(PLGC)、防治胃癌的有效作用机制之一。     

柴胡疏肝散加减治疗慢性萎缩性胃炎肝胃不和证的Meta分析*

目的系统评价柴胡疏肝散加减治疗慢性萎缩性胃炎(CAG)肝胃不和证的临床疗效以及安全性。方法 检索Pubmed,Web of Science,Cochrane Library,CNKI,VIP和万方数据库,纳入所有柴胡疏肝散加减治疗慢性萎缩性胃炎肝胃不和证的临床随机对照试验(RCTs),检索时间为建库至2019年10月1日,采用RevMan5.3软件进行Meta分析。结果 最终纳入11项研究,共1 068例患者。Meta分析结果显示:与常规西药治疗相比,柴胡疏肝散能有效提高肝胃不和型萎缩性胃炎患者的临床总有效率[RR=1.25,95%CI(1.19,1.33),P<0.000 01]、症状疗效总有效率[RR=1.57,95%CI(1.30,1.89）,P<0.000 01]及血清胃泌素G17水平[MD=3.61,95%CI(2.89,4.33),P<0.000 01],并能改善胃粘膜萎缩[MD=-1.53,95%CI(-1.93,-1.12),P<0.000 01]、肠上皮化生[MD=-0.79,95%CI(-0.96,-0.63),P<0.000 01]、异型增生度[MD=-0.69,95%CI(-0.84,-0.55),P<0.000 01]的病理检查积分,2组疗效差异具有统计学意义。结论 柴胡疏肝散加减治疗肝胃不和型慢性萎缩性胃炎疗效优于常规西药治疗。     

胃复春片联合复方丙谷胺西咪替丁慢性萎缩性胃炎的临床研究

目的观察胃复春片联合复方丙谷胺西咪替丁片治疗慢性萎缩性胃炎的临床疗效。方法选取2017年4月—2018年10月在三峡大学第二人民医院进行治疗的慢性萎缩性胃炎患者98例作为研究对象,将所有患者采用数字表法随机分为对照组和治疗组,每组各49例。对照组患者口服复方丙谷胺西咪替丁片,2片/次,3次/d。治疗组在对照组治疗的基础上口服胃复春片,4片/次,3次/d。所有患者均治疗4个月。观察两组患者的临床疗效,比较两组治疗前后的临床症状积分和血清学指标。结果治疗后,对照组和治疗组的总有效率分别为81.63%、93.88%,两组比较差异具有统计学意义(P0.05)。治疗后,两组胃刺痛、口干口苦、胃脘胀满、倦怠乏力和嗳气反酸评分均显著降低,同组治疗前后比较差异具有统计学意义(P0.05、0.01);且治疗后治疗组临床症状积分显著低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者胃泌素(GAS)明显下降,降钙素基因相关肽(CGRP)、血管内皮生长因子(VEGF)和一氧化氮(NO)水平均显著上升,同组治疗前后比较差异具有统计学意义(P0.05、0.01);且治疗后治疗组血清学指标显著优于对照组,两组比较差异具有统计学意义(P0.05)。结论胃复春片联合复方丙谷胺西咪替丁片治疗慢性萎缩性胃炎具有较好的临床疗效,可明显改善患者临床症状和血清学指标,具有一定的临床推广应用价值。     

Significant association of deficiency of hemoglobin, iron and vitamin B12, high homocysteine level, and gastric parietal cell antibody positivity with atrophic glossitis

J Oral Pathol Med (2012) 41 : 500–504 Background: Atrophic glossitis (AG) is considered to be a marker of nutritional deficiency. In this study, we evaluated whether there was an intimate association of the deficiency of hemoglobin, iron, vitamin B12 or folic acid, high blood homocysteine level, and serum gastric parietal cell antibody (GPCA) positivity with AG. Methods: The blood hemoglobin, iron, vitamin B12, folic acid, and homocysteine concentrations and the serum GPCA level in 176 AG patients were measured and compared with the corresponding levels in 176 age‐ and sex‐matched healthy control subjects. Results: We found that 39 (22.2%), 47 (26.7%), 13 (7.4%), and 3 (1.7%) AG patients had deficiencies of Hb (men < 13 g/dl, women < 12 g/dl), iron (<60 μg/dl), vitamin B12 (<200 pg/ml), and folic acid (<4 ng/ml), respectively. Moreover, 38 (21.6%) AG patients had abnormally high blood homocysteine level, and 47 (26.7%) AG patients had serum GPCA positivity. AG patients had a significantly higher frequency of Hb, iron, or vitamin B12 deficiency, of abnormally elevated blood homocysteine level, or of serum GPCA positivity than healthy control subjects (all P‐values = 0.000). However, no significant difference in frequency of folic acid deficiency was found between AG patients and healthy control subjects. Conclusion: We conclude that there is a significant association of deficiency of hemoglobin, iron and vitamin B12, abnormally high blood homocysteine level, and serum GPCA positivity with AG.     

应用数码显微镜评价重组牛碱性成纤维细胞生长因子辅助治疗萎缩性舌炎的临床效果

目的：应用数码显微镜观察重组牛碱性成纤维细胞生长因子（recombinantbovinebasicfibroblastgrowthfactor,rb-bFGF）辅助治疗萎缩性舌炎的疗效。方法：39例维生素B12缺乏的萎缩性舌炎患者,随机进入治疗组（21例）和对照组（18例）。采用数码显微镜,检测患者初次就诊及第7、14d复诊时舌乳头形态,同时记录舌痛、味觉改变的程度。比较两组患者在初诊及两次复诊时上述3项指标的改善情况。结果：第7d复诊,治疗组患者总体舌黏膜萎缩的改善程度高于对照组（P〈0．05）,其舌痛存在时间短于对照组护（P〈0．05）;第14d复诊,两组治疗效果趋于一致。结论：rbFGF能够减轻炎症反应、促进舌乳头生长并缩短疼痛时间。     

Hashimoto’s thyroiditis: TGAb,TPOAb, TRAb and recovery from hypothyroidism

Hashimoto described four patients with goiter. The histology of the goiter was characterized by diffuse lymphocytic infiltration, fibrosis and epithelial cell destruction. Thyroglobulin antibody (TGAb) and thyroid peroxidase antibody (TPOAb) have been used to diagnose Hashimoto’s thyroiditis. Patients with positive TGAb and/or TPOAb have been assumed to have Hashimoto’s thyroiditis. Approximately 10% of those with positive TGAb and/or TPOAb have hypothyroidism. There are two types of autoimmune thyroiditis: goitrous Hashimoto’s thyroiditis and atrophic thyroiditis. The latter patients have blocking antibody (thyroid-stimulating hormone [TSH]-stimulation blocking antibody [TSBAb]). TSBAb is a TSH-receptor antibody (TRAb). TSBAb causes thyroid atrophy and hypothyroidism. TGAb and/or TPOAb do not necessarily cause hypothyroidism. Hypothyroid patients with Hashimoto’s thyroiditis usually receive life-long l-thyroxine therapy. However, spontaneous recovery from hypothyroidism has been reported. Patients who had Hashimoto’s hypothyroidism and then Graves’ hyperthyroidism (and vice versa), have also been reported. Hashimoto’s hypothyroidism and Graves’ hyperthyroidism could be the opposite spectrums of one disease.     

谢晶日教授“三因制宜”论治慢性萎缩性胃炎

目的:探究谢晶日教授临证治疗慢性萎缩性胃炎辨证施治的诊疗及用药规律。,行临床拓宽思路,提高临床疗效。方法:以"三因制宜"为理论基础,理论联系实际,对谢晶日教授关于从时、地、人三因防治慢性萎缩性胃炎的经验进行搜集整理。结果:谢老师认为慢性萎缩性胃炎病其病位在胃,但与季节、气候、地域、环境、年龄、性别等密切相关。治疗时注重整体与部分的联系,内因与外因的结合,注意辨证与辨病的分析,方可达到临床疗效甚佳的效果。结论:通过阐述谢师治疗慢性萎缩性胃炎的诊治、用药规律及典型案例,使"三因制宜"论治慢性萎缩性胃炎的的思路更为清晰,临床疗效极佳。     

Reconstruction of the atrophic edentulous maxilla with free iliac crest grafts and implants: a 3-year report of a prospective clinical study

Purpose: The purpose of this study was to perform a longitudinal follow-up study of implant stability in grafted maxillae with the aid of clinical, radiological, and resonance frequency analysis (RFA) parameters. Materials and Methods: The atrophic edentulous maxillae in 29 patients were reconstructed with free iliac crest grafts using onlay/inlay or interpositional grafting techniques. The endpoint of the resorption pattern in the maxilla determined the grafting technique used. Endosteal implants were placed after 6 months of bone-graft healing. Implant stability was measured four times using RFA: when the implants were placed, after 6 to 8 months of healing, after 6 months and 3 years of bridge loading. Individual checkups were performed at the two later RFA registrations after removal of the supraconstructions (Procera® Implant Bridge, Nobel Biocare AB, Göteborg, Sweden). Radiological follow up of marginal bone level was performed annually. Results: Twenty-five patients remained for the follow-up period. A total of 192 implants were placed and with a survival rate of 90% at the 3-year follow up. Women and an implant position with a class 6 resorption prior to reconstruction were factors with significant increased risk for implant failure (multivariate logistic regression). Twelve of the 20 failed implants were lost before loading (early failures). The change in the marginal bone level was 0.3 ± 0.3 mm between baseline (bridge delivery) and the 3-year follow up. The implant stability quotient (ISQ) value for all implants differed significantly between abutment connection (60.2 ± 7.3) and after 6 months of bridge loading (62.5 ± 5.5) (Wilcoxon signed ranks test for paired data, p=.05) but were nonsignificant between 6 months of bridge loading and 3 years of bridge loading (61.8 ± 5.5). There was a significant difference between successful and failed implants when the ISQ values were compared for individual implants at placement (Mann-Whitney U test, p=.004). All 25 patients were provided with fixed implant bridges at the time of the 3-year follow up. Conclusion: This clinical follow up using radiological examinations and RFA measurements indicates a predictable and stable long-term result for patients with atrophic edentulous maxillae reconstructed with autogenous bone and with delayed placement of endosteal implants. The ISQ value at the time of placement can probably serve as an indicator of level of risk for implant failure.